1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Shionogi & Co., Ltd.
  6. News
  7. Summary
    4507   JP3347200002

SHIONOGI & CO., LTD.

(4507)
  Report
Delayed Japan Exchange  -  02:00 2022-08-19 am EDT
6900.00 JPY   -1.43%
08/10Ensitrelvir Fumaric Acid (S-217622), a Therapeutic Drug for COVID-19, Shows High In Vitro Antiviral Activity Against Omicron Subvariants BA.2.75
AQ
08/09Shionogi & Co., Ltd Announces Ensitrelvir Fumaric Acid (S-217622), Therapeutic Drug for COVID-19,Shows High In Vitro Antiviral Activity Against Omicron Subvariants BA.2.75
CI
08/05Shionogi & Co., Ltd. - Notice Regarding the Status (Progress Report) of Acquisition of Own Shares (Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Shionogi & Co., Ltd. - Notice Regarding Acquisition and Cancellation of Treasury Stock

06/24/2022 | 08:12am EDT

Osaka, Japan - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereafter 'Shionogi') announces information relating to the implementation of the acquisition of treasury stock and the cancellation of treasury stock, which were resolved at the Board of Directors meeting held on May 11, 2022. The acquisition and cancellation of the treasury stock was subject to the approval of shareholders at the General Meeting of Shareholders regarding the disposition of treasury stock by way of third-party allotment for the purpose of supporting the activities of the Shionogi Infectious Diseases Research Promotion Foundation, a General Incorporated Foundation. This time, this proposal was approved at the Ordinary General Meeting of shareholders held on June 23, 2022.

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Contact:

SHIONOGI

Website: https://www.shionogi.com

(C) 2022 Electronic News Publishing, source ENP Newswire

All news about SHIONOGI & CO., LTD.
08/10Ensitrelvir Fumaric Acid (S-217622), a Therapeutic Drug for COVID-19, Shows High In Vit..
AQ
08/09Shionogi & Co., Ltd Announces Ensitrelvir Fumaric Acid (S-217622), Therapeutic Drug for..
CI
08/05Shionogi & Co., Ltd. - Notice Regarding the Status (Progress Report) of Acquisition of ..
AQ
08/04Shionogi & Co Advances Share Buyback Program
MT
08/04SHIONOGI : Notice Regarding the Status (Progress Report) of Acquisition of Own Shares
PU
08/04SHIONOGI : and Grunenthal GmbH Enter a License Agreement to Commercialize Injectable Resin..
PU
08/04Grünenthal to license osteoarthritis pain treatment to Shionogi in Japan in deal of up ..
AQ
08/04Shionogi & Co., Ltd. and Grunenthal GmbH Enter a License Agreement to Commercialize Inj..
CI
08/03Japan Index Sees Steady Gains; Toyota Unit Hino Motors Commits Data Fraud for Almost Tw..
MT
08/02Shionogi's Fiscal Q1 Attributable Profit Rises Nearly 8%
MT
More news
Analyst Recommendations on SHIONOGI & CO., LTD.
More recommendations
Financials
Sales 2023 391 B 2 893 M 2 893 M
Net income 2023 145 B 1 077 M 1 077 M
Net cash 2023 507 B 3 751 M 3 751 M
P/E ratio 2023 14,2x
Yield 2023 1,74%
Capitalization 2 077 B 15 378 M 15 378 M
EV / Sales 2023 4,02x
EV / Sales 2024 4,03x
Nbr of Employees 5 693
Free-Float 90,1%
Chart SHIONOGI & CO., LTD.
Duration : Period :
Shionogi & Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHIONOGI & CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 6 900,00 JPY
Average target price 7 994,17 JPY
Spread / Average Target 15,9%
EPS Revisions
Managers and Directors
Isao Teshirogi Chairman & President
Yuji Hosogai Manager-Accounting & Finance
John Keller Senior Executive Officer, Head-R&D
Yasuetsu Imune Senior Executive Officer & GM-Research
Keiichi Ando Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
SHIONOGI & CO., LTD.-13.85%15 601
JOHNSON & JOHNSON-2.51%438 468
ELI LILLY AND COMPANY14.66%300 939
ROCHE HOLDING AG-15.60%275 743
PFIZER, INC.-17.73%272 648
ABBVIE INC.4.35%249 814